NCT06312423 (ECDA000/02) is a Phase 1 clinical trial of Oligonucleotides, Phosphorothioate in Immune System, sponsored by Ministry of Public Health of the Province of La Rioja.

Who is sponsoring NCT06312423?

NCT06312423 is sponsored by Ministry of Public Health of the Province of La Rioja.

What drugs are being tested in NCT06312423?

Interventions in NCT06312423: Oligonucleotides, Phosphorothioate.

What condition does NCT06312423 study?

NCT06312423 studies Immune System.

Is NCT06312423 still recruiting?

NCT06312423 is currently status unknown. Last updated 15 March 2024.

Last reviewed 2024-03-15 · How we verify

NCT06312423: ECDA000/02

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Safety and Pharmacokinetics of IMT504, an Immunomodulator and Tissue Repair Inducer

Status unknown Phase 1 Last updated 15 March 2024

What this trial tests

Phase 1 trial testing Oligonucleotides, Phosphorothioate in Immune System in 12 participants. Status unknown.

Timeline

23 February 2024

Primary endpoint
30 August 2024

30 December 2024

Quick facts

Lead sponsor	Ministry of Public Health of the Province of La Rioja
Phase	Phase 1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	non randomized
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	12
Start date	23 February 2024
Primary completion	30 August 2024
Estimated completion	30 December 2024
Sites	1 location across Argentina

Drugs / interventions tested

Oligonucleotides, Phosphorothioate — full drug profile →

Conditions studied

Immune System — all drugs for Immune System →

Sponsor

Ministry of Public Health of the Province of La Rioja

Who can join

18 and older, any sex, with Immune System. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Phase 1 open-label dose-escalation study to evaluate the safety and pharmacokinetics of IMT504 Phosphorothioate Oligonucleotide, an immunomodulator and tissue repair inducer, in healthy volunteers.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Immune System

Currently open trials in the same condition.

NCT07020156 — A First-in-Human Phase I Trial of OX118 in Healthy Volunteers · Phase 1 · recruiting
NCT06470607 — The Lymphocytic Infiltrate of Lung Tumors. · recruiting
NCT05334888 — Sex-differential Host-microbiome CVD Risk - A Longitudinal Cohort Approach · recruiting
NCT06683248 — The Effects of Night Shift Work on Health Across the Menstrual Cycle · NA · recruiting
NCT05026242 — Effects of Almond Consumption on Innate and Adaptive Immune System · NA · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06312423 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ministry of Public Health of the Province of La Rioja
Last refreshed: 15 March 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06312423.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing